SAB-185 advanced from Phase 2 to the Phase 3 portion of the ACTIV-2 trial based on meeting pre-defined graduation criteria. The interim analysis demonstrated that both the lower and higher doses of ...

Multiple variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged rapidly since the first identification of the virus in Wuhan, China, in late December 2019. The current ...

“These in vitro data demonstrating the efficacy of SAB-185 against the Delta and Lambda variants were produced to provide new insights into antibody binding to the SARS-CoV-2 spike variants, and as a ...

SIOUX FALLS, S.D., Jan. 24, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically ...

SIOUX FALLS, S.D., March 01, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, ...

SAB Biotherapeutics is hoping to continue work on its COVID-19 antibody treatment after the National Institutes of Health (NIH) shut down a funded phase 3 clinical trial when the omicron wave slowed ...

Positive clinical results confirm that SAB’s fully-human polyclonal antibodies can be broadly neutralizing to both known and unknown viral variants—a valuable feature when addressing rapidly mutating ...

Issued on March 31, 2022, SAB 121 required public companies holding crypto on behalf of their customers to record customer-held crypto assets on their balance sheets as both an asset and a ...

SIOUX FALLS, S.D.--(BUSINESS WIRE)-- SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully ...

SAB-185 advanced from Phase 2 to the Phase 3 portion of the ACTIV-2 trial based on meeting pre-defined graduation criteria. The interim analysis demonstrated that both the lower and higher doses of ...